Peringatan Keamanan

The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.

Golimumab

DB06674

biotech approved

Deskripsi

Golimumab is a human IgG1? monoclonal antibody derived from immunizing genetically engineered mice with human TNF?. Golimumab binds and inhibits soluble and transmembrane human TNF?. Increased TNF? is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Golimumab has a long half-life of about 2 weeks.
Volume Distribusi After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Klirens (Clearance) After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.

Absorpsi

After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 ± 1.4 ?g/mL.

Metabolisme

The metabolism of golimumab has yet to be determined.

Rute Eliminasi

The route of elimination for golimumab has yet to be determined.

Interaksi Obat

1334 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Golimumab.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Golimumab.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Golimumab.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Golimumab.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Golimumab.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Golimumab.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Golimumab.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Golimumab.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Golimumab.
Adalimumab The risk or severity of infection can be increased when Adalimumab is combined with Golimumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Golimumab.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Golimumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Golimumab.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Golimumab.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Golimumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Golimumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Golimumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Golimumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Golimumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Golimumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Golimumab.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Golimumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Golimumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Golimumab.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Golimumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Golimumab.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Golimumab.
Cladribine Golimumab may increase the immunosuppressive activities of Cladribine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Golimumab.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Golimumab.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Golimumab.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Golimumab.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Golimumab.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Golimumab.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Golimumab.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Golimumab.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Golimumab.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Golimumab.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Golimumab.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Golimumab.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Golimumab.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Golimumab.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Golimumab.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Golimumab.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Golimumab.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Golimumab.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Golimumab.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Golimumab.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Golimumab.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Golimumab.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Golimumab.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Golimumab.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Golimumab.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Golimumab.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Golimumab.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Golimumab.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Golimumab.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Golimumab.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Golimumab.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Golimumab.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Golimumab.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Golimumab.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Golimumab.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Golimumab.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Golimumab.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Golimumab.
Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Golimumab.
Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Golimumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Golimumab.
Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Golimumab.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Golimumab.
Stepronin The risk or severity of adverse effects can be increased when Stepronin is combined with Golimumab.
Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Golimumab.
Vorinostat The risk or severity of adverse effects can be increased when Vorinostat is combined with Golimumab.
2-Methoxyethanol The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Golimumab.
Brequinar The risk or severity of adverse effects can be increased when Brequinar is combined with Golimumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Golimumab.
Interferon alfa The risk or severity of adverse effects can be increased when Interferon alfa is combined with Golimumab.
Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Golimumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Golimumab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Golimumab.
Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Golimumab.
Abetimus The risk or severity of adverse effects can be increased when Abetimus is combined with Golimumab.
Belatacept The risk or severity of adverse effects can be increased when Golimumab is combined with Belatacept.
Pralatrexate The risk or severity of adverse effects can be increased when Golimumab is combined with Pralatrexate.
Wortmannin The risk or severity of adverse effects can be increased when Golimumab is combined with Wortmannin.
Eribulin The risk or severity of adverse effects can be increased when Golimumab is combined with Eribulin.
Belimumab The risk or severity of adverse effects can be increased when Golimumab is combined with Belimumab.
Teriflunomide The risk or severity of adverse effects can be increased when Golimumab is combined with Teriflunomide.
Carfilzomib The risk or severity of adverse effects can be increased when Golimumab is combined with Carfilzomib.
Dimethyl fumarate The risk or severity of adverse effects can be increased when Golimumab is combined with Dimethyl fumarate.
Obinutuzumab The risk or severity of adverse effects can be increased when Golimumab is combined with Obinutuzumab.
Secukinumab The risk or severity of adverse effects can be increased when Golimumab is combined with Secukinumab.
Siltuximab The risk or severity of adverse effects can be increased when Golimumab is combined with Siltuximab.
Blinatumomab The risk or severity of adverse effects can be increased when Golimumab is combined with Blinatumomab.
Dinutuximab The risk or severity of adverse effects can be increased when Golimumab is combined with Dinutuximab.
Tixocortol The risk or severity of adverse effects can be increased when Golimumab is combined with Tixocortol.
Peginterferon beta-1a The risk or severity of adverse effects can be increased when Golimumab is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Golimumab is combined with Antilymphocyte immunoglobulin (horse).
Tepoxalin The risk or severity of adverse effects can be increased when Golimumab is combined with Tepoxalin.

Target Protein

Tumor necrosis factor TNF

Referensi & Sumber

Synthesis reference: Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, Cohen SB, Rahman MU, Baker D, Mascelli MA, Davis HM, Everitt DE: Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007 Mar;47(3):383-96.
Artikel (PubMed)
  • PMID: 19489653
    Oldfield V, Plosker GL: Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs. 2009;23(2):125-35. doi: 10.2165/00063030-200923020-00005.
  • PMID: 23770005
    Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Jarnerot G, Rutgeerts P: Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):96-109.e1. doi: 10.1053/j.gastro.2013.06.010. Epub 2013 Jun 14.

Contoh Produk & Brand

Produk: 17 • International brands: 0
Produk
  • Simponi
    Injection, solution • 50 mg/0.5mL • Subcutaneous • US • Approved
  • Simponi
    Injection, solution • 100 mg/1mL • Subcutaneous • US • Approved
  • Simponi
    Solution • 100 mg / 1.0 mL • Subcutaneous • Canada • Approved
  • Simponi
    Solution • 50 mg / 0.5 mL • Subcutaneous • Canada • Approved
  • Simponi
    Solution • 50 mg / 0.5 mL • Subcutaneous • Canada • Approved
  • Simponi
    Solution • 100 mg / 1.0 mL • Subcutaneous • Canada • Approved
  • Simponi
    Injection, solution • 50 mg • Subcutaneous • EU • Approved
  • Simponi
    Injection, solution • 50 mg • Subcutaneous • EU • Approved
Menampilkan 8 dari 17 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul